Pharma Mar, S.A.
Pharma Mar, S.A. (0RC6.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Pharma Mar, S.A. (0RC6.L), featuring income statements, balance sheets, and cash flow data.
Pharma Mar, S.A. (0RC6.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Pharma Mar, S.A. 0RC6.L financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $38.86M | $48.36M | $45.66M | $42.87M |
| Cost of Revenue | $3.40M | $1.31M | $2.009M | $3.10M |
| Gross Profit | $35.46M | $47.05M | $43.65M | $39.78M |
| Gross Profit Ratio | $0.91 | $0.97 | $0.96 | $0.93 |
| R&D Expenses | $21.29M | $27.52M | $24.71M | $24.07M |
| SG&A Expenses | $13.68M | -$36.63M | $10.69M | $12.30M |
| Operating Expenses | $38.54M | $42.16M | $38.16M | $40.51M |
| Total Costs & Expenses | $41.94M | $43.47M | $40.17M | $43.60M |
| Interest Income | $0.00 | $4.80M | $0.00 | $931000.00 |
| Interest Expense | $819000.00 | $2.47M | $1.59M | $0.00 |
| Depreciation & Amortization | $1.99M | $2.13M | $1.54M | $1.55M |
| EBITDA | -$1.10M | $15.20M | $7.003M | $825000.00 |
| EBITDA Ratio | -$0.03 | $0.31 | $0.15 | $0.02 |
| Operating Income | -$3.08M | $4.89M | $5.48M | -$730000.00 |
| Operating Income Ratio | -$0.08 | $0.10 | $0.12 | -$0.02 |
| Other Income/Expenses (Net) | -$819000.00 | $4.65M | -$1.59M | $2.05M |
| Income Before Tax | -$3.90M | $9.54M | $3.89M | $1.32M |
| Income Before Tax Ratio | -$0.10 | $0.20 | $0.09 | $0.03 |
| Income Tax Expense | $45000.00 | -$9.14M | -$18000.00 | $87000.00 |
| Net Income | -$3.95M | $18.68M | $3.90M | $1.24M |
| Net Income Ratio | -$0.10 | $0.39 | $0.09 | $0.03 |
| EPS | -$0.23 | $1.06 | $0.22 | $0.07 |
| Diluted EPS | -$0.23 | $1.06 | $0.22 | $0.07 |
| Weighted Avg Shares Outstanding | $17.30M | $17.64M | $17.64M | $17.64M |
| Weighted Avg Shares Outstanding (Diluted) | $17.30M | $17.64M | $17.64M | $17.64M |
Over the last four quarters, Pharma Mar, S.A.'s revenue moved from $42.87M in Q2 2024 to $38.86M in Q1 2025. Operating income in Q1 2025 was -$3.08M, with a strong operating margin of -8%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Pharma Mar, S.A. remained robust at -$1.10M, reflecting operational efficiency. Net income dropped to -$3.95M, with an EPS of -$0.23. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan